Go Back   DreamTeamDownloads1, FTP Help, Movies, Bollywood, Applications, etc. & Mature Sex Forum, Rapidshare, Filefactory, Freakshare, Rapidgator, Turbobit, & More MULTI Filehosts > World News/Sport/Weather > EARTH: HEALTH-HISTORY-Enigmas-Astronomy-UFOs-Science-Animals

EARTH: HEALTH-HISTORY-Enigmas-Astronomy-UFOs-Science-Animals Read & Enjoy Many Interesting Articles in Here About our World -From the Past, Present & Future- Astronomy, Science and Technology, Archaeology, UFOs & Animals ..

IMPORTANT ANNOUNCEMENT
Hallo to All Members. As you can see we regularly Upgrade our Servers, (Sorry for any Downtime during this). We also have added more Forums to help you with many things and for you to enjoy. We now need you to help us to keep this site up and running. This site works at a loss every month and we appeal to you to donate what you can. If you would like to help us, then please just send a message to any Member of Staff for info on how to do this,,,, & Thank You for Being Members of this site.
Post New ThreadReply
 
LinkBack Thread Tools Display Modes
Old 10-03-16, 23:33   #1
 
Ladybbird's Avatar
 
Join Date: Feb 2011
Posts: 47,368
Thanks: 27,593
Thanked 14,456 Times in 10,262 Posts
Ladybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond repute

Awards Showcase
Best Admin Best Admin Gold Medal Gold Medal 
Total Awards: 8

Breaking News NEW UK Cancer Treatment Wipes Tumours in 11 DAYS

New Breast Cancer Treatment Wipes Out Tumours in Just 11 DAYS, 'Staggering' Trial Reveals

  • Doctors combined two existing cancer drugs - Tyverb and Herceptin
  • Cancer cells stopped producing in 87 per cent of the women during trial
  • Tumours were found to 'completely vanish' in 11 per cent of patients
  • Charities called it 'game-changing' for aggressive breast cancer treatment
Daily Mail UK, 10 March 2016


A new treatment for breast cancer has completely eradicated tumours in just 11 days.


Doctors today described the unexpected results as ‘staggering’ – and said the new two-pronged technique could spare thousands of women from gruelling chemotherapy.

The UK team, announcing their results at the European Breast Cancer Conference in Amsterdam, said they had never seen breast patients respond so quickly to a cancer treatment.


Women who were newly diagnosed with an aggressive form of breast cancer were given the therapy at 23 UK hospitals.

Of the participants in the trial the vast majority - 87 per cent – responded to the treatment, with tests showing that the cancer had stopped producing more cells.
But for some women the results were more dramatic.

In 11 per cent the tumours had completely vanished, to the surprise of surgeons, and for another 17 per cent they had significantly shrunk.





Doctors said the new two-pronged technique for breast cancer could spare thousands of women from gruelling chemotherapy treatment


Doctors combined two existing cancer drugs - Tyverb and Herceptin – and gave them to women as soon as they were diagnosed.

The team, led by the University of Manchester and the Institute of Cancer Research in London, had initially aimed simply to shrink tumours in the few days before surgery.


But when the surgeons tried to remove the lumps – which had measured up to 3cm wide just a few days earlier - they found that in some women the tumours had already vanished.

Study leader Professor Nigel Bundred, a cancer surgeon in Manchester, said: ‘For solid tumours to disappear in 11 days is unheard of. These are mind-boggling results.’

And Professor David Cameron, oncologist at Edinburgh University, said: ‘It was only when the pathologists were scratching around in the lab saying, “where is the tumour?”, that it became apparent that there was no tumour at all.’

The experts said that because the trial was relatively small – involving 257 women of whom 66 took the combination treatment – further tests are needed before they consider rolling the treatment out more widely.


These results are so staggering that we will have to run another trial to prove that they are generalisable

Professor Nigel Bundred, University of Manchester



But, while remaining cautious, they struggled to contain their excitement at the early results.

‘But it is clear what has happened – we are pretty certain that we are not only getting tumour disappearance – we are getting an immune response as well.’

The treatment was given to women with the HER2-positive form of breast cancer, which affects around 8,000 women in Britain every year.

Herceptin, which is delivered via a drip, is often used alongside chemotherapy to treat women with this form of the disease – but usually only after surgery in a bid to stop the cancer returning.

Tyverb, which is also known as Lapatinib, is a pill used for women with advanced breast cancer, usually when other treatments have failed and the disease has spread to other parts of the body.

By giving the combination right at the start, as soon as a woman was diagnosed, the researchers found they could eradicate the disease at the very beginning.

Women will still have to have surgery, to make sure no cancer cells are left - but the doctors hope it will mean they don't have to have chemotherapy afterwards.





Two existing cancer drugs - Tyverb and Herceptin (above) - were given to women. It was found to halt the production of new cancer cells in 87 per cent of patients


In combination, the drugs cost just under £1,500 for an 11-day course – and because Tyverb is nearing the end of its patent the cost is expected to plummet.

Professor Bundred said: ‘A large chunk of evolution is not about suddenly finding a new drug, it is about finding a new way to use the drugs we already have in a new way.
‘We have found a group of people who respond exquisitely well.’

Professor Judith Bliss, of the Institute of Cancer Research in London, said: ‘We set up the trial to see whether we could see which patients responded from a biological point of view.
‘But to see that we couldn’t even find the tumour left at all in some patients was very surprising.’

Cancer charities welcomed the findings – and called for more research so that the benefits can be quickly rolled out to patients.


For some HER2 positive breast cancer patients the effect of this drug combination will be amazing, and mean they can avoid chemotherapy and its gruelling side effects completely

Samia al Qadhi, chief executive, Breast Cancer Care



Samia al Qadhi, chief executive at Breast Cancer Care, said: ‘The astonishing findings in this study show that combining these two drugs has the potential to shrink HER2 positive breast cancer in just 11 days.
‘For some HER2 positive breast cancer patients the effect of this drug combination will be amazing, and mean they can avoid chemotherapy and its gruelling side effects completely.

‘For others, their tumours may not shrink, but doctors will know either way very quickly, giving them the ability to rapidly decide on further treatment.
‘Although an early study, this has game changing potential.

Baroness Delyth Morgan, chief executive at Breast Cancer Now, added: ‘We hope this particularly impressive combination trial will serve as a stepping stone to an era of more personalised treatment for HER2 positive breast cancer.

‘Such a rapid response before surgery could soon give doctors the unprecedented ability to identify women responding so well to combined HER2-targeting drugs that they would not need gruelling chemotherapy.

‘To confirm these hopes, we’ll now need to see the results replicated in larger trials and to understand how such a positive response to combined HER2-targeted drugs before surgery – and the avoidance of chemotherapy – could impact on survival.’

Professor Arnie Purushotham of Cancer Research UK, which funded the study, said: ‘These results are very promising if they stand up in the long run and could be the starting step of finding a new way to treat HER2 positive breast cancers.
‘This could mean some women can avoid chemotherapy after their surgery - sparing them the side-effects and giving them a better quality of life.’



Quote:

HOW DOES THE TREATMENT WORK?

Some 8,000 of the 50,000 women diagnosed with breast cancer in Britain every year have the HER2 positive form of the disease, which tends to be more aggressive.

These tumours are more deadly, because they have HER2 (human epidermal growth factor) proteins on the surface of normal breast cells, which accelerates the growth of cancers.





Combining the treatment was found to stop cancer cells reproducing and shrunk some women's tumours completely



The outcomes for women with HER2 positve cancer in the past were very poor – with many women seeing their tumours returning soon after surgery. But a decade ago Herceptin – the first gene-targeted ‘wonder drug’ – changed their lives.

Given after surgery, and alongside chemotherapy, Herceptin boosted five-year survival from 66 per cent to 95 per cent.

Now, a new approach to treatment could improve survival rates even further, while removing the need for months and months of gruelling chemotherapy.

The new approach takes Herceptin and combines it with another powerful drug called Tyverb – and gives it to women in the very first days after they are diagnosed with breast cancer.

One drug attacks cancer cells from the outside, and the other burrows inside cells and attacks it from the inside. Doctors think this twin attack provides a ‘total block’ – stopping cancer cells dividing and rapidly killing them off.

Early trials showed that the vast majority of women responded to the treatment, and for one in ten women their tumours simply vanished within 11 days.

Women given the combination will still need surgery to check that the tumour has disappeared, and to remove any remaining cells. But doctors hope that they will not need to undergo further treatments.

Herceptin, given via a drip, latches on to the surface of the cell, stopping the HER2 protein working. Tyverb is given as a pill, working inside the cancer cells and blocking the HER2 signals that make the cells grow.
In combination, the drugs also appear to boost the body’s immune response.

__________________
PUTIN TRUMP & Netanyahu Will Meet in HELL










TRUMP WARNS; 'There'll Be a Bloodbath If I Don't Get Elected'


PLEASE HELP THIS SITE..Click DONATE
& Thanks to ALL Members of ... 1..

THIS SITE IS MORE THAN JUST WAREZ...& TO STOP SPAM-IF YOU WANT TO POST, YOUR FIRST POST MUST BE IN WELCOMES
Ladybbird is online now  
Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiTweet this Post!
Reply With Quote
Old 10-07-16, 01:00   #2
 
Ladybbird's Avatar
 
Join Date: Feb 2011
Posts: 47,368
Thanks: 27,593
Thanked 14,456 Times in 10,262 Posts
Ladybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond repute

Awards Showcase
Best Admin Best Admin Gold Medal Gold Medal 
Total Awards: 8

Breaking News UK Scientists/Docs Test LESS PAIN/MORE Air For Lung Disease Patients

Nerve Zapper That's a Breath of Fresh Air For Lung Disease Patients:
Balloon Treatment Offers New hope for Those Living in Pain > Gasping for Air



  • Operation for those with chronic obstructive pulmonary disease (COPD)
  • Hour-long procedure works by burning away a patient's damaged nerves
  • Signals from nerves make airwaves narrow making patients short of breath
  • During procedure electrode placed inside balloon and burns nerves away
Daily Mail UK, 9 July 2016.



Sufferers of severe lung disease are being offered a remarkable new surgical treatment which uses tiny electrodes to burn away nerves that make them feel breathless.


The operation, which is being tested on NHS patients at the Royal Brompton and Chelsea and Westminster Hospitals in London, is the latest hope for those with chronic obstructive pulmonary disease (COPD) – an umbrella term for conditions causing lung damage, including chronic bronchitis and emphysema.


COPD affects many millions throughout the world.




The hour-long procedure works by burning away damaged nerves, and in doing so prevents the abnormal narrowing of the airways and over-production of mucus.







Pictured, how the new treatment works - a catheter with an electrode inside a deflated ‘balloon’ is introduced through a tube and then inflated to hold the electrode in place



In patients with COPD, nerves in the lungs become overactive, often because of damage caused by smoking. Chemical signals from these nerves prompt the airways in the lungs to contract and narrow, so patients feel very short of breath.


The same faulty nerves also make the lungs release much more mucus, so patients can cough and wheeze.


Patients are typically given medication delivered through inhalers which acts against these chemical signals.


These drugs, called bronchodilators, allow the airways to relax and open so the patient can breathe more easily.


But Dr Pallav Shah, consultant physician at the hospitals taking part in the international clinical trial, called AIRFLOW-1, says: ‘Inhalers only work temporarily, can be distributed irregularly within the lungs, and may cause side effects such as blurred vision and urine retention in a small number of patients.

‘They are also short-acting, and patients may forget to take them.’


The latest procedure uses a device called the dNerva Dual Cooled RF Catheter, which destroys branches of the vagus nerve in the lungs. The nerve is responsible for muscle contraction and mucus secretion.


During the procedure, doctors insert a narrow tube with a light and camera at its tip into the airways under general anaesthetic. A catheter with an electrode inside a deflated ‘balloon’ is introduced through the tube, and then inflated to hold the electrode in place. Radiofrequency energy delivered through the tip destroys the nerve branches


‘It’s rather like tackling an overgrown tree halfway up,’ says Dr Shah. ‘If you can burn away the signals part-way down, far fewer are coming through so the airways are no longer constricting all the time, and less mucus is produced, so patients can breathe more easily.’


Dr Shah has now treated eight patients at the Royal Brompton as part of the international trial. In total, 80 patients have been treated worldwide.
‘So far the results are looking very hopeful, and many patients report that the shortness of breath goes immediately,’ he says.
‘This procedure keeps obstructed airways open to improve breathing, and has the potential to provide a permanent improvement for all patients with COPD.’


Patients still take medication. ‘But if medication gives a ten per cent improvement in symptoms, and we can increase this to an 18 to 20 per cent improvement using this procedure, then in time some patients may be able to give up the medication completely,’ says Dr Shah.


Gillian Joseph, 72, was one of the first patients to take part in the trial. The grandmother-of-five, from Bushey, Hertfordshire, had the hour-long procedure in April after living with emphysema for 18 years. She had smoked for 30 years, but she gave up once she was diagnosed.



Quote:
‘After a few steps I couldn’t walk anywhere or do anything,’ she says. ‘I hated the way I was – I just wanted my life back.
‘But I was noticeably less breathless immediately after having my treatment at the Royal Brompton. Now I can go shopping and walk around normally for the first time in many years.




Dr Nick Hopkinson, honorary medical adviser to the British Lung Foundation and reader in respiratory medicine at Imperial College London, says:



‘This is a new approach to treating people with COPD, and early data suggests that it could be very helpful. However, we still need larger trials to see how well it works in clinical care.


‘Overactivity of nerves in the airways in people with COPD causes the airways to narrow, making it harder to breathe.
‘Until now, we have been able to reverse this using inhaled medications such as tiotropium, helping to open up the airways.

‘This new approach means that instead of giving medication which block the effects of the nerves, we are destroying the nerves which supply these areas. This has been trialled already in a fairly small number of patients, suggesting that it is fairly safe and early data suggest that it is effective.


‘We now need larger-scale trials to determine how effective it is and how many people it can help, and whether it works best alongside medication to open up the airways or as a standalone treatment making that medication unnecessary.’
END



N.B : IMPORTANT FOR OUR MANY MEMBERS, who suffer from similar conditions..

This thread is made a 'STICKY'..

Please post your comments/??? on here and we will advise/update accordingly as best that we can..


Sometimes even Doctors can get it wrong... when they haven't
lived/experienced similar conditions for many years, as have their patients....

.
__________________
PUTIN TRUMP & Netanyahu Will Meet in HELL










TRUMP WARNS; 'There'll Be a Bloodbath If I Don't Get Elected'


PLEASE HELP THIS SITE..Click DONATE
& Thanks to ALL Members of ... 1..

THIS SITE IS MORE THAN JUST WAREZ...& TO STOP SPAM-IF YOU WANT TO POST, YOUR FIRST POST MUST BE IN WELCOMES
Ladybbird is online now  
Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiTweet this Post!
Reply With Quote
The Following User Says Thank You to Ladybbird For This Useful Post:
Tarfoot (10-07-16)
Post New ThreadReply


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On



Powered by vBulletin® Version 3.8.11
Copyright ©2000 - 2024, vBulletin Solutions Inc.
SEO by vBSEO 3.5.2
Designed by: vBSkinworks